Broomfield biotech firm Accera names Charles Stacey president, CEO

BROOMFIELD – Biotechnology company Accera Inc. on Tuesday announced that it has appointed Charles Stacey as president and chief executive

Stacey had served as interim CEO since February, taking over day-to-day leadership responsibilities of the company from chairman Claude Nash

Broomfield-based Accera is a clinical-stage biotech company focused on developing therapies for central nervous system disorders. Its lead product candidate is AC-1204, a ketosis-inducing compound aimed at treating Alzheimer’s disease. AC-1204 is in a Phase 3 clinical study in patients with mild to moderate Alzheimer’s

SPONSORED CONTENT

Federal District Court Rules Corporate Transparency Act Unconstitutional . . . But Most Small Businesses Must Still Comply

Lyons Gaddis Real Estate and Business Attorney Cameron Grant shares important details of the Corporate Transparency Act (CTA).

Stacey takes over a company that employs about 30 people.

Prior to joining Accera, Stacey served as an investment manager with London-based venture capital firm Inventages, which is an investor in Accera. Before that, he co-founded Flexycast, a medical device company in the United Kingdom. He began his health-care career as a reconstructive and orthopedic surgeon in London.